Effective Treatment for Recurrent Ovarian Cancer Guided by Drug Sensitivity from Ascites-Derived Organoid: A Case Report
Wanyi Chen,Po-Han Fang,Bin Zheng,Yue Liang,Yiwen Mao,Xuefeng Jiang,Qionglan Tang
DOI: https://doi.org/10.2147/IJWH.S405010
2023-07-14
Abstract:Wanyi Chen, 1, &ast Po-Han Fang, 2, &ast Bin Zheng, 3 Yue Liang, 1 Yiwen Mao, 1 Xuefeng Jiang, 1 Qionglan Tang 4 1 Department of Obstetrics and Gynecology, the First Affiliated Hospital of Jinan University, Guangzhou, People's Republic of China; 2 International School, Jinan University, Guangzhou, People's Republic of China; 3 Guangdong Research Center for Organoid Engineering and Technology, Guangzhou, People's Republic of China; 4 Department of Pathology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, People's Republic of China &astThese authors contributed equally to this work Correspondence: Qionglan Tang, Email So far, ovarian cancer has still been the most lethal gynecological malignancy. The chemotherapy and targeted medication are the mainstay for the recurrent ovarian cancer treatment. About 70% of the advanced-stage cases will relapse. Ascites-derived organoid is a pre-clinical model for the precise prediction of the therapeutic effectiveness for the ovarian cancer: it can be used to assess the drug sensitivity, to guide individualized precise treatment, and to improve advanced stage as well as recurrent ovarian cancer patient' survival and prognosis. Until now, there has been no report concerning the establishment of the organoid out of the patient's ascites and the concurrent usage of drug sensitivity test to guide the individualized precise treatment for the ovarian cancer. Here, we report a case of recurrent ovarian cancer of a 59-year-old female patient whose CA125 at its peak increased to 4523.4 U/mL. Then, patient's own ovarian cancer organoid was constructed from the ascites by the abdominocentesis; concurrently, medication sensitivity test was performed on the organoid to guide individualized precise treatment. After the treatment, CA125 decreased to 33.7 U/mL, and the patient's condition relieved effectively. This is the first published case report using ascites-derived organoid and the drug sensitivity test thereof to guide the precise treatment of recurrent ovarian cancer. Keywords: ascites-derived organoid, ovarian cancer organoid, recurrent ovarian cancer, drug sensitivity test, precise treatment Ovarian cancer is a common gynecologic cancer worldwide, and ranks second in cancer death of female reproductive malignancies, and 90% of ovarian cancer are of an epithelial cell type and comprise multiple histologic types, with various specific molecular changes, clinical behaviours, and treatment outcomes. The remaining 10% are non-epithelial ovarian cancers – mainly germ cell tumours and sex cord-stromal tumours – with much more favourable prognosis. 1,2 Ovarian cancer is a heterogeneous disease, of which the epithelial ovarian cancer (EOC) is the most common form. EOC develops according to two different carcinogenic pathways. Type I EOCs are suggested to be relatively indolent and genetically stable tumors that typically arise from recognizable precursor lesions, such as endometriosis or borderline tumors with low malignant potential. In contrast, type II EOCs are proposed to be high-grade, biologically aggressive tumors from their outset, with a propensity for metastasis from small-volume primary lesions. 3 The outcomes of EOC patients vary, depending on the stage at diagnosis. Although the 5-year survival rate of about 70% could be reached for early-stage detection, the vast majority of patients are diagnosed at advanced stage with only 5-year survival rate of 34%. 4 Recurrence is the major factor resulting in the low survival rate of advanced EOC, for the recurrence rate is higher in the advanced stage than the early stage; nowaday proteomics analysis of ovarian cancer, as well as their adaptive responses to therapy, can uncover new therapeutic choices, which can reduce the emergence of drug resistance and potentially improve patient outcomes, but there has been no satisfactory treatment until now. 5–7 The platinum-based chemotherapy is currently used as first-line therapeutic regimen after primary surgery and still recommended for the platinum-sensitive recurrent ECO that relapses after 12 months. 8 In contrast, in recurrent platinum-resistant ECO, though studies had shown results preferring single-agent due to the drug toxicity, there was no evidence for a preferred sequence, neither for a preferred therapeutic agent. 8,9 In addition, the increased heterogeneity of the disease and individual heterogeneity could lead to diverse clinical response to the same drug. Therefore, a pre-clinical model, which could predict the clinical efficiency of a pharmacologic agent, could assist physician to plan the therapeutic regimen. Patient-derived tumor organoid -Abstract Truncated-
obstetrics & gynecology